Delayed emesis: moderately emetogenic chemotherapy (Q35953416)

11 August 2017

1 reference

title

Delayed emesis: moderately emetogenic chemotherapy. (English)

1 reference

11 August 2017

1 reference

Fausto Roila

1

1 reference

11 August 2017

David Warr

2

1 reference

11 August 2017

Rebecca A Clark-Snow

3

1 reference

11 August 2017

Maurizio Tonato

4

1 reference

11 August 2017

Richard J Gralla

5

1 reference

11 August 2017

Lawrence H Einhorn

6

1 reference

11 August 2017

Jorn Herrstedt

7

1 reference

11 August 2017

publication date

12 November 2004

1 reference

Supportive Care in Cancer

11 August 2017

published in

1 reference

11 August 2017

volume

13

1 reference

11 August 2017

issue

2

1 reference

11 August 2017

page(s)

104-108

1 reference

Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron

11 August 2017

cites work

1 reference

12 December 2020

ESMO Recommendations for prophylaxis of chemotherapy-induced nausea and vomiting (NV)

1 reference

12 December 2020

Ondansetron compared with granisetron in the prophylaxis of cyclophosphamide-induced emesis in out-patients: a multicentre, double-blind, double-dummy, randomised, parallel-group study. Emesis Study Group for Ondansetron and Granisetron in Breast Ca

1 reference

12 December 2020

Transferability to clinical practice of the results of controlled clinical trials: the case of antiemetic prophylactic treatment for cancer chemotherapy-induced nausea and vomiting. Italian Group for Antiemetic Research

1 reference

12 December 2020

Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology

1 reference

12 December 2020

Role of maintenance oral dexamethasone in prophylaxis of delayed emesis caused by moderately emetogenic chemotherapy

1 reference

12 December 2020

Chemotherapy-induced emesis: management of early and delayed emesis in milder emetogenic regimens.

1 reference

12 December 2020

The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy

1 reference

12 December 2020

ASHP Therapeutic Guidelines on the Pharmacologic Management of Nausea and Vomiting in Adult and Pediatric Patients Receiving Chemotherapy or Radiation Therapy or Undergoing Surgery

1 reference

12 December 2020

Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron

1 reference

12 December 2020

Transferring scientific evidence to oncological practice: a trial on the impact of three different implementation strategies on antiemetic prescriptions

1 reference

12 December 2020

Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Instit

1 reference

12 December 2020

Prophylaxis of delayed nausea and vomiting after cancer chemotherapy

1 reference

12 December 2020

Randomized, double-blind, dose-finding study of dexamethasone in preventing acute emesis induced by anthracyclines, carboplatin, or cyclophosphamide:.

1 reference

12 December 2020

Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy

1 reference

12 December 2020

Delayed emesis induced by moderately emetogenic chemotherapy: do we need to treat all patients? The Italian Group for Antiemetic Research

1 reference

12 December 2020

Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy.

1 reference

12 December 2020

Prevention of chemotherapy- and radiotherapy-induced emesis: results of Perugia Consensus Conference. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC)

1 reference

12 December 2020

Randomized study of dexamethasone treatment for delayed emesis, anorexia and fatigue induced by irinotecan

1 reference

12 December 2020

10.1007/S00520-004-0700-8

Identifiers

DOI

1 reference

11 August 2017

1 reference